

08/31/00
JC912 U.S. PTO

09-01-00

A

Attorney Docket No.: 5665.400-US

PATENT

1000662 U.S. PTO
09/05/2000
08/31/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

EXPRESS MAIL CERTIFICATE

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Re: U.S. Patent Application for
Title: Novel Proteases and Variants Thereof
Applicants: Nørregaard-Madsen et al.

Sir:

Express Mail Label No. EL 473439624US

Date of Deposit : August 31, 2000

I hereby certify that the following attached paper(s) or fee

1. Filing Under 37 C.F.R. 1.53(b) (in duplicate)
2. Patent Application
3. Unexecuted Combined Declaration and Power of Attorney
4. Preliminary Amendment

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington, DC 20231.

Carol McFarlane
(Name of person mailing paper(s) or fee)

Carol McFarlane
(Signature of person mailing paper(s) or fee)

Mailing Address:
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10017
(212) 867-0123

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FILING UNDER 37 C.F.R. 1.53(b)

Box Patent Application
Assistant Commissioner for Patents
Washington, DC 20231

Express Mail Label No. EL 473439624US
Date of Deposit August 31, 2000

10862 U.S. PTO
109/652743
08/31/00



Sir:

This is a request for filing a continuation-in-part application under 37 C.F.R. 1.53(b) of

Applicant(s): Nørregaard-Madsen et al.

Title: Novel Proteases and Variants Thereof

89 pages of specification 1 page of abstract

5 sheets of Formal Drawings 25 pages of sequence listing

3 sheets of Declaration and Power of Attorney

The filing fee is calculated as follows:

Basic Fee: \$690.00

Total Claims: $13 - 20 = 0 \times 18 =$ \$0

Independent Claims: $3 - 3 = 0 \times 78 =$ \$0

Total Fee: \$690.00

Priority of Danish application nos. PA 1999 01212 and PA 1999 01500 filed on August 31, 1999 and October 20, 1999, respectively, is claimed under 35 U.S.C. 119. A certified copy of each application will be submitted at a later date.

Priority of U.S. provisional application no. 60/156,743 filed on September 30, 1999 is claimed under 35 U.S.C. 119.

The benefit of application no. 09/551,826 filed on April 17, 2000 in the U.S. is claimed under 35 U.S.C. 120.

Address all future communications to Steve T. Zelson, Esq., Novo Nordisk of North America, Inc., 405 Lexington Avenue, Suite 6400, New York, NY 10174-6401.

Please charge the required fee, estimated to be \$690, to Novo Nordisk of North America, Inc., Deposit Account No. 14-1447. A duplicate of this sheet is enclosed.

Respectfully submitted,

Date: August 31, 2000


Elias J. Lambiris, Reg. No. 33,728
Novo Nordisk of North America, Inc.
405 Lexington Avenue, Suite 6400
New York, NY 10174-6401
(212) 867-0123